Concordance of Circulating Tumor DNA, Primary and Metastatic Tissue DNA, and Immunohistochemistry in Gastroesophageal Carcinoma - PubMed
5 hours ago
- #biomarker testing
- #cancer genomics
- #liquid biopsy
- The study assessed concordance between ctDNA, tDNA, and IHC in gastroesophageal carcinoma, involving 345 patients with ctDNA testing at Mayo Clinic.
- ctDNA testing had a shorter median turnaround time than tDNA (6 vs. 13 days), with TP53 being the most frequent alteration across all modalities.
- High concordance rates were observed: ≥78.8% for ctDNA and primary tDNA, ≥84.8% for ctDNA and metastatic tDNA, and higher IHC-ctDNA concordance in metastatic tumors.
- IHC-ctDNA concordance in metastatic tumors was 91.1% for HER2/ERBB2 and 97.7% for MMR/MSI, compared to 81.1% and 95.8% in primary tumors.
- Triplet concordance for MSI/MMR was 97.6% in primary and 100% in metastatic tumors, while ERBB2/HER2 was 84.4% and 93.9%, with ctDNA showing temporal heterogeneity in some patients.